Dihexa

Dihexa is a synthetic peptide derived from angiotensin IV, a component of the renin-angiotensin system. It is classified as an extremely potent nootropic and is currently a research compound with no regulatory approval. How it works: Dihexa promotes new synapse formation - the physical connections between neurons that underlie learning and memory. Its mechanism is angiotensin-IV receptor activity, which has been shown in preclinical research to powerfully support synaptic growth. Who tends to use it: Its only goal rating is cognition, at the primary level. It tends to attract people with serious cognitive goals - those looking for meaningful support for learning and memory, often after exhausting gentler nootropic options. How it is taken: Dihexa can be taken orally or applied topically. Dosing is described as 'low mg, per protocol' - specific doses are not published in general ranges because of how potent this compound is and how early-stage the human data remains. Timing is in the morning, and cycles are kept short. What to expect: Preclinical data suggests substantial effects on synaptic density. Human experience is anecdotal. It may take time before effects are noticeable, as synapse formation is a gradual biological process. Safety: The record notes two important cautions. First, Dihexa is very potent, and long-term human safety data is lacking. Second, there is a caution with cancer history - because it promotes cellular growth, anyone with a personal history of cancer should not use it. It carries a cancer-history excludeIf flag, which means it would not be recommended for those patients. As an early-stage research compound, Dihexa is only appropriate after a careful consult. Your licensed provider in the PepDepo network will set your protocol and dose if this peptide is right for you.